Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention

Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
Roger Crystal, M.D., Chief Executive Officer, will be a Panelist on “Biology of Pain and Addiction - Next Generation Treatments for Pain and Addiction,” and Present a Corporate Overview

SANTA MONICA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will participate in a panel at the BIO International Convention, being held June 4-7, 2018, in Boston, Massachusetts. Dr. Crystal will be a panelist on “Biology of Pain and Addiction – Next Generation Treatments for Pain and Addiction,” which will be held within a broader session, entitled “Opioids: Changing the Paradigm on Treating Pain and Addiction.”

The panel, which takes place on Tuesday, June 5, 2018, at 11:00 AM ET, will focus on understanding the biology underlying pain and addiction that are critical to supporting the discovery of novel and safer treatments for both pain and addiction, as well as for ensuring that patients receive the right treatment at the right time, with the right support, and without stigma. Panel participants will discuss the science behind the next generation of treatments for pain and addiction and what this could mean for combatting the opioid epidemic.

Separately, Dr. Crystal will also present a corporate overview of Opiant Pharmaceuticals on the same day at 1:00 PM ET at the conference.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first product, NARCAN® Nasal Spray, is exclusively licensed to Adapt Pharmaceuticals, and is approved for marketing in the U.S. and Canada. For more information please visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746

Primary Logo

Source: Opiant Pharmaceuticals, Inc.